The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

Epigenetics

Volumn 8, Issue 11, 2013, Pages 1226-1235

  Türbachova, Ivana ^a   Schwachula, Tim ^a   Vasconcelos, Ines ^a   Mustea, Alexander ^b   Baldinger, Tina ^a   Jones, Katherine A ^c   Bujard, Hermann ^d   Olek, Alexander ^e   Olek, Klaus ^f   Gellhaus, Katharina ^a   Braicu, Ioana ^g   Könsgen, Dominique ^b   Fryer, Christy ^h   Ravot, Elisabetta ⁱ   Hellwag, Alexander ^a   Westerfeld, Nicole ^j   Gruss, Oliver J ^d   Meissner, Markus ^k   Hasan, Mazahir ^l   Weber, Michael ^a   Hoffmüller, Ulrich ^a   Zimmermann, Sven ^a   Loddenkemper, Christoph ^m   Mahner, Sven ⁿ   Babel, Nina ^g   Berns, Els ^o   Adams, Richard ^p   Zeilinger, Robert ^q   Baron, Udo ^a   Vergote, Ignace ^r   Maughan, Tim ^s   Marme, Frederik ^d   Dickhaus, Thorsten ^t   Sehouli, Jalid ^g   Olek, Sven ^a   more..

^a EPIONTIS GMBH   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Nobel Education ^*  (Germany)

^f Labor für abstammungsbegutachtung   (Czech Republic)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h NOVARTIS   (United States)

ⁱ Saatchi and Saatchi health   (Italy)

^j IDEXX LABORATORIES   (United States)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^m PaThOTREs Gemeinschaftspraxis für Pathologie und Neuropathologie   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p CARDIFF UNIVERSITY   (United Kingdom)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r UNIVERSITY OF LEUVEN   (Belgium)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t HUMBOLDT UNIVERSITY   (Germany)

more..

Author keywords

Epigenetic immunophenotyping; ImmunoCRIT; Ovarian cancer; Regulatory T cells; T lymphocytes; Tumor immunology; Tumor metastasis

Indexed keywords

OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD; BRONCHUS CANCER; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; KIDNEY CANCER; MALE; METASTASIS; OVARY CANCER; POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

EPIGENETIC IMMUNOPHENOTYPING; IMMUNOCRIT; OVARIAN CANCER; REGULATORY T CELLS; T LYMPHOCYTES; TUMOR IMMUNOLOGY; TUMOR METASTASIS;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNE TOLERANCE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84887443903     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.26334     Document Type: Article

References (45)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-360; P M I D: 15 0 32 5 81; http://dx.doi. o r g /10.114 6 /annurev. immu nol. 22.012703.10 4 8 03
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998; PMID:12407406; http://dx.doi.org/10.1038/ni1102 -991
3. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-1174; PMID:174763 46; http://dx.doi.org/10.1172/ JCI31202
4. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241-246; PMID:18508251; http://dx.doi.org/10.1016/j. coi.2008.04.008
5. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-562; P M I D: 15 0 3 25 8 8; http://dx.doi.org/10.1146/annurev.immu nol. 21.12 0 6 01.14112 2
6. Khattri R, Cox T, Yasayko S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-342; PMID:12612581; http://dx.doi.org/10.1038/ni909
7. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336; PMID:12612578; http://dx.doi. org/10.1038/ni904
8. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329-341; PMID:15780990; http://dx.doi.org/10.1016/j.immuni.2005.01.016
9. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061; PMID:12522256; http://dx.doi.org/10.1126/science.1079490
10. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13:108-116; PMID:17257897; http://dx.doi. org/10.1016/j.molmed.2007.01.003
11. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92:913-920; P M I D: 15 7 14 2 0 5; http://dx.doi.org/10.1038/sj.bjc.6602407
12. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65:2457-2464; P M I D: 15 7 8 1 6 6 2; http://dx.doi. org/10.1158/0008-5472.CAN-04-3232
13. Liyanage UK, Moore T T, Joo H-G, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761; PMID:12193750
14. Gray CP, Arosio P, Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res 2003; 9:2551-2559; PMID:12855630
15. Viguier M, Lemaître F, Verola O, Cho M-S, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-1453; PMID:15240741
16. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089-1099; PMID:12942579; http://dx.doi. org/10.1002/cncr.11618
17. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-4408; PMID:14555512
18. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55:1064-1071; PMID:16328385; http://dx.doi.org/10.1007/ s00262-005-0092-8
19. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11:8326-8331; PMID:16322292; http://dx.doi.org/10.1158/1078-0432.CCR-05-1244
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949; PMID:15322536; http:// dx.doi.org/10.1038/nm1093
21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964; PMID:170 08531; http://dx.doi.org/10.1126/ science.1129139
22. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-5380; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584
23. Keino H, Takeuchi M, Kezuka T, Hattori T, Usui M, Taguchi O, et al. Induction of Eye-Derived Tolerance Does Not Depend on Naturally Occurring CD4+CD25+ T Regulatory Cells. Investigative Ophthalmology &. Visual Science 2006; 47:1047-1055
24. McPherson SW, Heuss ND, Gregerson DS. Regulation of CD8(+) T Cell Responses to Retinal Antigen by Local FoxP3(+) Regulatory T Cells. Front Immunol 2012; 3:166; P M I D: 2 2 73 7153; http:// dx.doi.org/10.3389/fimmu.2012.00166
25. Cervantes-Barragán L, Firner S, Bechmann I, Waisman A, Lahl K, Sparwasser T, Thiel V, Ludewig B. Regulatory T cells selectively preserve immune privilege of self-antigens during viral central nervous system infection. J Immunol 2012; 188:3678-3685; PMID:22407917; http://dx.doi.org/10.4049/ jimmunol.1102422
26. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol 2008; 3:221-47; PMID:18233952; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.151523
27. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698-2705; PMID:12173339; http://dx.doi.org/10.1002/ cncr.10541
28. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-1664; PMID:15084698; http://dx.doi.org/10.1056/NEJMra030831
29. Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, et al. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol 2010; 21:2201-2225; PMID:20439341; http://dx.doi.org/10.1093/annonc/mdq229
30. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, 2008.
31. Kolles H, Stegmaier C, von Seebach HB, Ziegler H. Deskriptive Epidemiologie und Prognose maligner gynäkologischer Tumoren. Geburtshilfe Frauenheilkd 1989; 49:573-578; PMID:2787260; http://dx.doi.org/10.1055/s-2008-1035842
32. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18(Suppl 2):S33-50; P M I D: 157614 65; http://dx.doi.org/10.1038/ modpathol.3800307
33. Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3:349-58; P M I D: 115 7 83 6 8; http://dx.doi. org/10.1046/j.1525-1438.1993.03060349.x
34. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5:e38; PMID:17298177; http://dx.doi.org/10.1371/journal. pbio.0050038
35. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, Baron U, Stauch D, Kotsch K, Pratschke J, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69:599-608; PMID:19147574; http://dx.doi.org/10.1158/0008-5472.CAN-08-2361
36. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37:2378-2389; PMID:17694575; http://dx.doi.org/10.1002/eji.200737594
37. Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmüller U, Grützkau A, Lohneis P, Dickhaus T, Gröne J, Kruschewski M, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011; 6:236-246; PMID:20962591; http://dx.doi.org/10.4161/epi.6.2.13755
38. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561-577; PMID:8472349
39. Jonckheere AR. A test of significance for the relation between m rankings and k ranked categories. Br J Stat Psychol 1954; 7:93-100; http://dx.doi.or g /10.1111/j. 2044-8 317.1954.tb0014 8.x
40. Page EB. Ordered hypotheses for multiple treatments: a significance test for linear ranks. J Am Stat Assoc 1963; 58:216-230; http://dx.doi.org/10.1080/016214 59.1963.10500843
41. Chekerov R, Koensgen D, Klaman I, Rosenthal A, Oskay-Oezcelik G, Mustea A, et al. Tumor- and stromal cell-specific expression of topoisomerase IIa and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study. Mol Med Report 2009; 2:1011-1016; http://dx.doi.org/10.3892/ mmr_00000207
42. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, et al.; International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95:105-112; PMID:12529343; http://dx.doi.org/10.1093/ jnci/95.2.113
43. Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer 2012; 11:69; PMID:22978347; http:// dx.doi.org /10.1186 /1476-4598-11-69
44. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, et al.; MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2 011; 12:642-653; PMID:21641867; http://dx.doi.org/10.1016/S1470-2045(11)70102-4
45. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002; 47:68-75; PMID:11873711